Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486574 | 0.81 | KMT2A (0.38) | TLR2 | |
| SCHEMBL3486287 | 0.76 | ENTPD2 (0.35) | P2RY12 | |
| SCHEMBL3486986 | 0.72 | SLC28A1 (0.48) | P2RY2 | |
| SCHEMBL9069548 | 0.68 | P2RY12 (0.36) | P2RY12P2RY2 | |
| SCHEMBL6223334 | 0.66 | P2RY12 (0.34) | P2RY12 | |
| SCHEMBL10458515 | 0.66 | LMNA (0.43) | NT5E | |
| SCHEMBL9069521 | 0.65 | P2RY2 (0.35) | P2RY12NT5EP2RY2P2RY1 | |
| SCHEMBL564852 | 0.62 | P2RY12 (0.44) | P2RY12P2RY2P2RY1 | |
| SCHEMBL27984222 | 0.61 | KMT2A (0.54) | TLR2 | |
| SCHEMBL16360194 | 0.61 | KMT2A (0.54) | TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100036115-A1 | Novel Compositions for the Delivery of Negatively Charged Molecules | SIRNA THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7553830-B2 | Compositions for the delivery of negatively charged molecules | SIRNA THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1724254-A2 | Novel compositions for the delivery of negatively charged molecules | Sirna Therapeutics, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20030073640-A1 | Novel compositions for the delivery of negatively charged molecules | RIBOZYME PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6395713-B1 | CATIONIC LIPIDCATIONIC LIPID | RIBOZYME PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036115-A1 | Novel Compositions for the Delivery of Negatively Charged Molecules | PHAX, TARBP1, SNRPE | P2RY12 3713/4885NT5E 221/4885TLR2 2564/4885 |
| US-20030073640-A1 | Novel compositions for the delivery of negatively charged molecules | PHAX, TARBP1, SNRPE | P2RY12 3713/4885NT5E 221/4885TLR2 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.